- t2cure’s cell therapy is available through clinical centres working with us
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies conducted by the founders at Goethe University, Frankfurt.
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
Overview/Mission
t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases like myocardial infarction or peripheral artery occlusive disease.
Today’s standard therapies for acute myocardial infarction are acute reperfusion and stenting of the respective coronary artery as well as anti-thrombotic therapies. These therapies cannot avoid the later sequelae of the disease, namely ventricular remodelling. Since the human heart only has very limited ability to regenerate itself it can normally not compensate for the consequences of an acute myocardial infarction, namely tissue damage in the affected region of the heart and massive cell death due to oxygen deprivation. For both, acute myocardial infarction and chronic ischemic heart diseases, this leads to an increased morbidity and mortality for patients.
t2cure is a biopharmaceutical company founded by Prof. Andreas M. Zeiher and Prof. Stefanie Dimmeler. The founders of t2cure have developed a therapeutic approach to effectively induce neo-vascularization and cardiac repair processes: The goal is to increase cardiac regeneration on top of standard therapies, to improve ventricular function and to increase the number of viable and functional cells in the diseased cardiac tissue, thereby ameliorating the effects of cardiac remodelling with the long term goal of reducing morbidity and mortality of patients with large myocardial infarctions and depressed left ventricular contractile function. The same approach is used for the peripheral artery occlusive disease of the limbs.
The new therapeutics consist of autologous progenitor cells prepared from a patient’s own bone marrow. These progenitor cells have the potential to induce repair and healing processes in cardiac or peripheral tissues. The cells are administered via catheter into the coronary arteries of a diseased heart or into peripheral arteries of the limbs in a routine procedure.